2. Search Result
Search Result
Results for "

lipogenesis

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

4

Peptides

12

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139576B
    Larsucosterol (trimethylamine)

    DUR-928 (trimethylamine)

    		 LXR Endogenous Metabolite Metabolic Disease
    Larsucosterol (DUR-928) trimethylamine, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol trimethylamine as a potent endogenous regulator decreases lipogenesis. Larsucosterol trimethylamine inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .
    Larsucosterol (trimethylamine)
  • HY-W058849
    MT 63-78

    		AMPK mTOR Apoptosis Cancer
    MT 63-78 is a specific and potent direct AMPK activator with an EC50 of 25 μM. MT 63–78 also induces cell mitotic arrest and apoptosis. MT 63-78 blocks prostate cancer growth by inhibiting the lipogenesis and mTORC1 pathways. MT 63-78 has antitumor effects .
    MT 63-78
  • HY-12756A
    E6446 dihydrochloride
    3 Publications Verification

    		 Toll-like Receptor (TLR) Stearoyl-CoA Desaturase (SCD) Metabolic Disease Inflammation/Immunology
    E6446 dihydrochloride is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 dihydrochloride is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 dihydrochloride also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .
    E6446 dihydrochloride
  • HY-12756
    E6446
    3 Publications Verification

    		 Toll-like Receptor (TLR) Stearoyl-CoA Desaturase (SCD) Metabolic Disease Inflammation/Immunology
    E6446 is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .
    E6446
  • HY-W564704
    (p-Hydroxybenzyl)malonic acid

    		Drug Derivative Metabolic Disease
    (p-Hydroxybenzyl)malonic acid is a hydroxyphenyl derivative capable of inhibiting insulin-induced lipogenesis in rat adipocytes with an IC50 value of 3.8 μM .
    (p-Hydroxybenzyl)malonic acid
  • HY-139576
    Larsucosterol

    DUR-928

    		 LXR Endogenous Metabolite Metabolic Disease
    Larsucosterol (DUR-928), a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol as a potent endogenous regulator decreases lipogenesis. Larsucosterol inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .
    Larsucosterol
  • HY-139576A
    Larsucosterol sodium

    DUR-928 sodium

    		 LXR Endogenous Metabolite Metabolic Disease
    Larsucosterol (DUR-928) sodium, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol sodium as a potent endogenous regulator decreases lipogenesis. Larsucosterol sodium inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .
    Larsucosterol sodium
  • HY-139576C
    Larsucosterol ammonium

    DUR-928 ammonium

    		 LXR Endogenous Metabolite Metabolic Disease
    Larsucosterol (DUR-928) ammonium, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol ammonium as a potent endogenous regulator decreases lipogenesis. Larsucosterol ammonium inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .
    Larsucosterol ammonium
  • HY-169159
    SIRT6 activator 2

    		Sirtuin Metabolic Disease
    SIRT6 activator 2 (compound 31) is a sirtuin 6 activator with anti-lipid accumulation properties. SIRT6 activator 2 significantly downregulates LXR, SREBP-1c, and their target genes associated with lipogenesis, and can be used for research related to lipid metabolism-related diseases .
    SIRT6 activator 2
  • HY-N15691
    Tadehaginoside

    		Keap1-Nrf2 NF-κB Metabolic Disease Inflammation/Immunology
    Tadehaginoside, a phenylpropanoid glycoside, is a regulator of lipogenesis and glucose consumption. Tadehaginoside has antioxygenic property. Tadehaginoside mediates liver protection against oxidative stress injury and inflammation by regulating Nrf2 and NF-κB signaling pathways in hepatocytes. Tadehaginoside can be used for the study of obesity and diabetes .
    Tadehaginoside
  • HY-12756AR
    E6446 dihydrochloride (Standard)

    		Toll-like Receptor (TLR) Stearoyl-CoA Desaturase (SCD) Metabolic Disease Inflammation/Immunology
    E6446 (dihydrochloride) (Standard) is the analytical standard of E6446 (dihydrochloride). This product is intended for research and analytical applications. E6446 dihydrochloride is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 dihydrochloride is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 dihydrochloride also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .
    E6446 dihydrochloride (Standard)
  • HY-N0458
    Pedunculoside
    1 Publications Verification

    		 Fatty Acid Synthase (FASN) Metabolic Disease
    Pedunculoside exerts lipid-lowering effects partly through the regulation of?lipogenesis?and?fatty acid β-oxidation .
    Pedunculoside
  • HY-119006
    L-640,033

    		Adrenergic Receptor Endocrinology
    L-640,033 is a potent agonist of β-adrenergic. L-640,033 play an important role in lipid metabolism, and growth .
    L-640,033
  • HY-136374
    Haloxyfop-P-methyl

    		Herbicide Others
    Haloxyfop-P-methyl is an aryloxyphenoxypropionate herbicide. Haloxyfop-P-methyl can be absorbed by roots or foliage and hampers lipogenesis and increases oxidative stress in target plants .
    Haloxyfop-P-methyl
  • HY-137996
    Dehydrovomifoliol

    		Akt mTOR Metabolic Disease
    Dehydrovomifoliol is a AKT/mTOR dual inhibitor. Dehydrovomifoliol reduces lipid accumulation and lipogenesis by inhibiting the AKT/mTOR signaling pathway. Dehydrovomifoliol is used in nonalcoholic fatty liver disease research (NAFLD) .
    Dehydrovomifoliol
  • HY-D1163
    Chromium(III) acetate
    1 Publications Verification

    Chromium acetate; Chromic acetate; Chromium triacetate

    		 AMPK Metabolic Disease
    Chromium(III) acetate (Chromic acetate) is an AMPK inhibitor that promotes lipogenesis by inhibiting AMPK phosphorylation. Chromium(III) acetate has low toxicity in mammals, with an LD50 of 2365 mg/kg in rats .
    Chromium(III) acetate
  • HY-N0458R
    Pedunculoside (Standard)

    		Reference Standards Fatty Acid Synthase (FASN) Metabolic Disease
    Pedunculoside (Standard) is the analytical standard of Pedunculoside. This product is intended for research and analytical applications. Pedunculoside exerts lipid-lowering effects partly through the regulation of lipogenesis and fatty acid β-oxidation .
    Pedunculoside (Standard)
  • HY-119248
    KRP-297

    MK-0767

    		 PPAR Metabolic Disease
    KRP-297 is a PPARα and PPARγ agonist potentially for the research of type 2 diabetes and dyslipidemia. KRP-297 restores reduced lipid oxidation, and inhibits of enhanced lipogenesis and triglyceride accumulation in the liver.
    KRP-297
  • HY-N4104
    Agaric acid

    Agaricinic Acid

    		 Mitochondrial Metabolism Bacterial Calcium Channel Infection Metabolic Disease
    Agaric acid (Agaricinic Acid) is an orally active inhibitor of adenine nucleotide translocase found in specific fungi. Agaric acid can inhibit the biofilm formation of various bacteria such as Salmonella. Agaric acid can also induce mitochondrial permeability transition, prompting mitochondria to release Ca 2+, disrupting the transmembrane potential, and causing mitochondrial swelling. In addition, Agaric acid can also inhibit citrate transport in liver mitochondria and participate in the inhibition of fatty acid synthesis, affecting multiple metabolic processes .
    Agaric acid
  • HY-136374R
    Haloxyfop-P-methyl (Standard)

    		Herbicide Reference Standards Others
    Haloxyfop-P-methyl (Standard) is the analytical standard of Haloxyfop-P-methyl. This product is intended for research and analytical applications. Haloxyfop-P-methyl is an aryloxyphenoxypropionate herbicide. Haloxyfop-P-methyl can be absorbed by roots or foliage and hampers lipogenesis and increases oxidative stress in target plants .
    Haloxyfop-P-methyl (Standard)
  • HY-134969
    TFCA

    		LXR Metabolic Disease
    TFCA is a liver X receptor α (LXRα) antagonist. TFCA inhibits ligand-activated LXRα coactivation and transcriptional expression of the downstream target genes involved in fatty acid synthesis. TFCA attenuates ligand-induced lipogenesis and fatty liver by selectively inhibiting LXRα in the liver .
    TFCA
  • HY-N15691A
    (E)-Tadehaginoside

    		Keap1-Nrf2 NF-κB Metabolic Disease Inflammation/Immunology
    (E)-Tadehaginoside is the E-isomer of Tadehaginoside (HY-N15691). Tadehaginoside, a phenylpropanoid glycoside, is a regulator of lipogenesis and glucose consumption. Tadehaginoside has antioxygenic property. Tadehaginoside mediates liver protection against oxidative stress injury and inflammation by regulating Nrf2 and NF-κB signaling pathways in hepatocytes. Tadehaginoside can be used for the study of obesity and diabetes .
    (E)-Tadehaginoside
  • HY-128973
    Pyropheophorbide-a

    		Reactive Oxygen Species (ROS) Cancer
    Pyropheophorbide-a (Ppa) is a photosensitizer used in photodynamic therapy (PDT) for tumors. Pyropheophorbide-a exhibits phototoxic effects on tumor cells, such as cervical cancer cells, and also has anti-lipogenesis activity. Pyropheophorbide-a shows potential for research in the fields of cancer and age-related macular degeneration (AMD). Pyropheophorbide-a derivatives also demonstrate inhibitory activity against tumor cells .
    Pyropheophorbide-a
  • HY-149987
    LY3522348

    KHK-IN-3

    		 Ketohexokinase Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    KHK-IN-3 (Example 1) is a ketohexokinase (KHK) inhibitor. KHK-IN-3 can be used in the study of kidney disease, nonalcoholic steatohepatitis (NASH), diabetes and heart failure. KHK is a rate-limiting enzyme and fructokinase involved in fructose metabolism. KHK catalyzes the phosphorylation of fructose to fructose-1-phosphate (FIP) at the expense of ATP. The lack of feedback inhibition of fructose metabolism triggers the accumulation of downstream intermediates such as lipogenesis, gluconeogenesis, and oxidative phosphorylation .
    LY3522348
  • HY-149540
    CTL-06

    		Fatty Acid Synthase (FASN) Cancer
    CTL-06 is an inhibitor of Fatty Acid Synthase (FASN) (IC50: 3 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research .
    CTL-06
  • HY-128973R
    Pyropheophorbide-a (Standard)

    		Reactive Oxygen Species (ROS) Cancer
    Pyropheophorbide-a (Standard) is the analytical standard of Pyropheophorbide-a. This product is intended for research and analytical applications. Pyropheophorbide-a (Ppa) is a photosensitizer used in photodynamic therapy (PDT) for tumors. Pyropheophorbide-a exhibits phototoxic effects on tumor cells, such as cervical cancer cells, and also has anti-lipogenesis activity. Pyropheophorbide-a shows potential for research in the fields of cancer and age-related macular degeneration (AMD). Pyropheophorbide-a derivatives also demonstrate inhibitory activity against tumor cells .
    Pyropheophorbide-a (Standard)
  • HY-164997
    15-keto Prostaglandin F1α

    15-keto PGF1α

    		 Endogenous Metabolite Metabolic Disease
    15-keto Prostaglandin F1α (15-keto PGF1α) is a prostaglandin F1α metabolite. 15-keto Prostaglandin F1α (15-keto PGF1α) is an effective substrate for PGR-2. 15-keto Prostaglandin F1α (15-keto PGF1α) can be used to study physiological processes such as prostaglandin metabolism and lipogenesis .
    15-keto Prostaglandin F1α
  • HY-N0723
    Neomangiferin

    		Others Metabolic Disease
    Neomangiferin is a natural C-glucosyl xanthone isolated from m the dried rhizome of Anemarrhena asphodeloides. Neomangiferin has significant therapeutic effects on high-fat diet-induced nonalcoholic fatty liver disease (NAFLD) in rats .
    Neomangiferin
  • HY-N0723R
    Neomangiferin (Standard)

    		Reference Standards Others Metabolic Disease
    Neomangiferin (Standard) is the analytical standard of Neomangiferin. This product is intended for research and analytical applications. Neomangiferin is a natural C-glucosyl xanthone isolated from m the dried rhizome of Anemarrhena asphodeloides. Neomangiferin has significant therapeutic effects on high-fat diet-induced nonalcoholic fatty liver disease (NAFLD) in rats .
    Neomangiferin (Standard)
  • HY-149541
    CTL-12

    		Fatty Acid Synthase (FASN) Cancer
    CTL-12 is an inhibitor of fatty acid synthase (FASN) (IC50: 2.5 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research .
    CTL-12
  • HY-N7005
    Clitorin

    		EGFR Cytochrome P450 Fatty Acid Synthase (FASN) Acetyl-CoA Carboxylase HMG-CoA Reductase (HMGCR) PPAR AMPK Metabolic Disease Inflammation/Immunology Cancer
    Clitorin is an orally active flavonoid compound that can be isolated from Carica papaya. Clitorin is an inhibitor of EGFR (IC50: 89.58 nM) and aromatase (IC50: 77.41 nM). Clitorin has antioxidant and anti-tumor activities. In the DPPH and ABTS radical scavenging assays, Clitorin has IC50 values of 91.96 ppm and 250.45 ppm, respectively. In addition, Clitorin can regulate lipogenesis and fatty acid oxidation and can be used in the research of non-alcoholic fatty liver disease .
    Clitorin
  • HY-168049
    ZLY06

    		PPAR Akt Metabolic Disease
    ZLY06 is an orally active dual agonist of peroxisome proliferator-activated receptor (PPAR) δ and γ (PPAR δ: EC50=341 nM; PPAR γ: EC50=237 nM). ZLY06 induces hepatic lipid accumulation by inhibiting the phosphorylation of AKT1, mediating the upregulation of CD36. In addition, ZLY06 significantly improves glucose and lipid metabolism without increasing body weight, and alleviates fatty liver by promoting β-oxidation of fatty acids and inhibiting hepatic lipogenesis .
    ZLY06
  • HY-146288
    LXR agonist 2

    		LXR Metabolic Disease
    LXR agonist 2 (compound 18rr) is a potent LXR (liver X receptor) agonist. LXR agonist 2 can stabilize NCOA1 (co-activator), leading to LXR agonism .
    LXR agonist 2
  • HY-114118
    Semaglutide
    Maximum Cited Publications
    18 Publications Verification

    		 GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide
  • HY-114118B
    Semaglutide acetate
    Maximum Cited Publications
    18 Publications Verification

    		 GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide acetate is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide acetate
  • HY-114118A
    Semaglutide TFA
    Maximum Cited Publications
    18 Publications Verification

    		 GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide TFA is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide TFA
  • HY-114118F
    Semaglutide, FITC labeled

    		GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide, FITC labeled is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide, FITC labeled promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide, FITC labeled also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide, FITC labeled has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide, FITC labeled can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide, FITC labeled
  • HY-114118S3
    Semaglutide-13C6,15N TFA

    		Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Metabolic Disease
    Semaglutide- 13C6, 15N TFA is the 13C- and 15N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide-13C6,15N TFA
  • HY-108022A
    Azemiglitazone potassium
    1 Publications Verification

    MSDC-0602K

    		 Insulin Receptor PPAR Metabolic Disease
    Azemiglitazone potassium (MSDC-0602K), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC50 of 18.25 μM . Azemiglitazone potassium modulates the mitochondrial pyruvate carrier (MPC). Azemiglitazone potassium can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance . Azemiglitazone potassium, an insulin sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide .
    Azemiglitazone potassium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: